Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fucosylated autologous bone marrow mesenchymal stem cells (Red de Terapia Celular)
- Development stage
- Unknown
- Lead developer
- Red de Terapia Celular
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Fucosylated autologous bone marrow mesenchymal stem cells (BM-MSCs) is an experimental cell therapy being developed by Red de Terapia Celular for the treatment of established osteoporosis and low-impact fractures. The therapy involves harvesting a patient's own bone marrow cells, expanding the mesenchymal stem cell population under GMP conditions, and applying an ex vivo fucosylation process. This enzymatic modification adds fucose residues to cell surface glycoproteins, creating ligands for E-selectin. This process, known as GPS (Glycosyltransferase-Programmed Stereosubstitution), is designed to significantly enhance the cells' ability to home to the bone marrow (osteotropism) following intravenous administration. Once localized in the bone, these MSCs are intended to rebalance bone remodeling by stimulating osteoblast differentiation and bone formation while inhibiting osteoclast-mediated resorption.
- Other names
- fucosylated BM-MSCsfucosylated mesenchymal stem cellsTerCel fucosylated MSCs
02
Targets
SELE (E-selectin)
Beyond the preview
Go deeper on fucosylated autologous bone marrow mesenchymal stem cells (Red de Terapia Celular).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fucosylated autologous bone marrow mesenchymal stem cells (Red de Terapia Celular).